Novartis eyes accelerated FDA approval for iptacopan across multiple indications

cafead

Administrator
Staff member
  • cafead   Oct 02, 2023 at 10:22: AM
via Novartis unveiled positive top-line Phase III results for iptacopan in IgA nephropathy and plans talks with the FDA to obtain accelerated approval in 2024.

article source